Newsletter Subject

Daily Headlines: Nuclear War Remains a Global Health Threat

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Mon, Dec 5, 2016 12:05 PM

Email Preheader Text

Daily Headlines December 5, 2016 [RepathaTM MDs: Help Get Patients Started on RepathaTM] [Non-Small

Daily Headlines December 5, 2016 [Nuclear War Remains a Global Health Threat] [Pearls From: Orrin Devinsky, MD] [RSNA: Protons Destroy Centrally Located Lung Cancer] [D.C. Week: Trump Taps Price for HHS; Medicaid Expert to Run CMS] [Study: Watch for PSE in Chronic Stroke Patients] Additional Resources [Diagnosis and Treatment of Relapsed Myeloma] [AML: Beware of Pre-leukemic Clones Surviving Chemotherapy] [Boosting Lung Cancer Outcomes in Diabetics] Industry Resources [Site For Endocrinologists Low Testosterone Due To Certain Medical Conditions. Treatment Info.] [RepathaTM (evolocumab) MDs: Help Get Patients Started on RepathaTM] [Myelomatosis A Treatment Option For Previously Treated Multiple Myeloma. HCP Site.] Recent Headlines ['It's Just Grossly Irresponsible': What We Heard This Week] [2015 Health Spending Tops $3.2 Trillion] [This Week in Zika: Texas Sees First Local Transmission] [Methotrexate Greatly Underprescribed for U.S. RA Patients] CME/CE [Lady Doc: Use Menopause Symptoms to Motivate] ADVERTISEMENT This Week's Survey [Is Price Right for HHS?] [President-elect Trump has named a well-known][conservative congressman and physician, Rep. Tom Price, MD], to lead the Department of Health and Human Services. CME Spotlights [Chronic Lymphocytic Leukemia w/ Watson @POC] [Source: @Point of Care] [Non-Small Cell Lung Cancer (NSCLC) @POC (WATSON)|Grant] [Source: @Point of Care] [Clinical Context: Multiple Myeloma] [Source: Projects in Knowledge, Inc.] [Multiple Myeloma (MM) @POC|Grant|App] [Source: @Point of Care] [Prostate Cancer @POC] [Source: @Point of Care] [Managing the Patient with Metastatic Melanoma: A Comprehensive, Evidence-Based Approach] [Source: Robert Michael Educational Institute LLC (RMEI)] [Immuno Oncology] [Source: @Point of Care] [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Initial Visits] [Source: Robert Michael Educational Institute LLC (RMEI)] [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Follow-up Visits] [Source: Robert Michael Educational Institute LLC (RMEI)] [Biosimilars--Can you explain extrapolation? Interchangeability? Substitution?] [Source: The France Foundation] [Playing The Offense In Advanced Basal Cell Carcinoma: A Team Approach To Treatment And Management] [Source: RMEI] [MDS and Acute Myeloid Leukemia (MDS and AML) @POC] [Source: @Point of Care] [Skin Cancers @Point of Care] [Source: @Point of Care] [Gynecologic Cancers @POC] [Source: @Point of Care] [Clinical Context: Prostate Cancer] [Source: Projects In Knowledge, Inc.] [Breast Cancer @POC w/Watson] [Source: @Point of Care] More of Today's Stories [Can Patients With Stable CML Stop Drug Therapy?] [Slow Medicine: Pressing Pause on Statins For Primary Prevention] [By the Numbers: For Sickest Patients, Costs Vary Widely by Geography] [Survival Boost With Liposomal Tx in Older AML Patients] [Novel Sickle Cell Tx Shows Promise for Pain Crises] [PICC in Kids Linked to Clotting Risk] [New FIRST Analysis: Trainees Prefer Loose Limits on Duty Hours] [Tweets of the Week: World AIDS Day and Drug Prices] [Rest in Peace, Obamacare] [PodMed: A Medical News Roundup From Johns Hopkins] [Glucocorticoids Linked to Organ Damage in SLE] CME/CE [Your Brain on Scrabble: That's Improbable!] More news from MedPage Today® Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. © 2016 Medpage Today, LLC. All rights reserved. Use of this site constitutes acceptance of the [MedPageToday.com] [terms of use] and [privacy policy]. The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Medpage Today is located at 345 Hudson Street, New York, NY 10014 [Remove me from this list] [Manage my e-mail settings]

Marketing emails from medpagetoday.com

View More
Sent On

02/07/2024

Sent On

02/07/2024

Sent On

02/07/2024

Sent On

01/07/2024

Sent On

01/07/2024

Sent On

01/07/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.